What's Happening?
EyePoint Pharmaceuticals, Inc. announced it is discontinuing its wet age-related macular degeneration (AMD) program and reducing its workforce by approximately 53%. This decision follows the failure of its experimental drug, DURAVYU (vorolanib intravitreal
insert), to meet the primary endpoint of non-inferiority in its Phase 3 LUCIA study for wet AMD. This marks the second late-stage failure for DURAVYU in wet AMD, prompting the company to conclude its pivotal Phase 3 wet AMD trials early. Despite vision improvements in treated patients, the drug did not prove as effective as the standard treatment, Regeneron's Eylea (aflibercept), in preserving eyesight. The company will now reallocate resources to its diabetic macular edema (DME) program, with pivotal Phase 3 data for DURAVYU in DME expected in the fourth quarter of 2027. The workforce reduction is expected to generate annualized savings of approximately $30 million, with most cuts occurring in Q4 2026 and completing in H1 2027.
Why It's Important?
This development is significant for the biotechnology sector and patients suffering from wet AMD. The failure of DURAVYU in late-stage trials highlights the inherent risks and challenges in drug development, even for promising candidates. For EyePoint Pharmaceuticals, the decision to halt the wet AMD program and implement substantial workforce reductions underscores the financial and operational pressures faced by biotech companies when clinical trials do not yield desired results. The shift in focus to the DME program indicates a strategic pivot to preserve value and pursue other therapeutic avenues. For patients with wet AMD, this means a potential new treatment option will not be available, reinforcing the reliance on existing therapies like Eylea. The job cuts also have a direct impact on the biotech employment landscape, reflecting the volatility of the industry.
What's Next?
EyePoint Pharmaceuticals will now concentrate its efforts and resources on the development of DURAVYU for diabetic macular edema (DME). The company anticipates releasing pivotal Phase 3 topline data from its COMO and CAPRI trials for DME in the fourth quarter of 2027. These trials are evaluating DURAVYU 2.7 mg against aflibercept in patients with active DME, with non-inferiority in visual acuity as the primary endpoint. The workforce reduction will proceed as planned, with the majority of the approximately 53% cut expected by the end of 2026 and completion in the first half of 2027. The company will incur charges of approximately $9 million related to employee separation benefits. The success or failure of the DME program will be critical for EyePoint's future viability and strategic direction.
Beyond the Headlines
The repeated late-stage failures of DURAVYU in wet AMD raise questions about the efficacy of its mechanism of action or delivery system in this specific indication, despite its potential in DME. This situation underscores the complexity of ophthalmic drug development, where subtle differences in disease pathology or drug delivery can significantly impact outcomes. The company's reliance on its proprietary Durasert E delivery technology, designed for sustained drug release, will be further scrutinized as the DME trials progress. This event also highlights the broader trend in the biotech industry where companies must make difficult decisions to prioritize pipelines and manage resources effectively in the face of clinical setbacks. The impact on investor confidence and future funding for similar long-acting ophthalmic drug candidates could also be a ripple effect.
